Stocks

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Experiences Notable Short Interest Growth

Published January 21, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has seen a significant increase in short interest this December. As of December 31, the total short interest reached 6,000,000 shares, reflecting a rise of 6.0% from the previous total of 5,660,000 shares on December 15. With an average trading volume of 250,800 shares, this leads to a days-to-cover ratio of 23.9 days. Currently, about 31.2% of the company’s stock is sold short.

Get Dianthus Therapeutics alerts:

Hedge Funds Adjust Their Positions in Dianthus Therapeutics

Recent changes have been noted among large investors regarding their stakes in Dianthus Therapeutics. Quest Partners LLC significantly increased its stake by an impressive 112,400.0% during the third quarter, now owning 1,125 shares valued at approximately $31,000 after acquiring an extra 1,124 shares. During the fourth quarter, SG Americas Securities LLC raised its holdings by 9.2%, bringing their total to 9,653 shares worth around $210,000 after purchasing an additional 814 shares. The Manufacturers Life Insurance Company initiated a new investment in Dianthus Therapeutics valued at about $236,000 during the second quarter. Fred Alger Management LLC boosted its position by 52.5% in the third quarter, now holding 9,633 shares valued at $264,000 after an extra purchase of 3,316 shares. Lastly, Point72 DIFC Ltd also established a new position in the company worth $334,000 in the second quarter. A noteworthy 47.53% of the stock is now controlled by hedge funds and other institutional investors.

Insights from Wall Street Analysts

Dianthus Therapeutics has recently been featured in multiple research reports. On December 20, TD Cowen initiated coverage on the company, issuing a "buy" rating. Oppenheimer increased its price target from $48.00 to $52.00 and rated the stock as "outperform" on November 11. On December 12, Raymond James upgraded Dianthus Therapeutics to a "moderate buy" rating, while HC Wainwright reaffirmed a "buy" rating with a price target of $40.00. A total of eight analysts have rated the stock as a buy, with two giving it a strong buy rating. According to MarketBeat.com, the average rating for the stock is "Buy" with an average target price of $46.43.

Get Our Latest Stock Report on Dianthus Therapeutics

Dianthus Therapeutics Sees Stock Price Increase

On a recent trading day, DNTH stock rose by 4.1%, increasing by $0.79 to reach $20.00. This trading session saw a volume of 156,254 shares compared to the average of 199,749 shares. The company possesses a market capitalization of $592 million, a price-to-earnings ratio of -8.00, and a beta of 1.74. The stock has a 50-day moving average of $23.62 and a 200-day moving average of $26.40, experiencing a yearly low of $10.65 and a high of $33.77.

Dianthus Therapeutics announced its quarterly earnings on November 7, revealing a loss of ($0.74) earnings per share (EPS) for the quarter, which was below analysts' expectations of ($0.59) by a margin of ($0.15). The company reported a staggering negative net margin of 1,250.32% and a negative return on equity of 21.68%. For the quarter, Dianthus Therapeutics generated revenue of $2.17 million, exceeding the consensus estimate of $1.07 million. Analysts predict that the company will reach an EPS of -2.61 in the current year.

Overview of Dianthus Therapeutics

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology firm focused on developing complement therapeutics designed to address severe autoimmune and inflammatory diseases. Notably, the company is working on DNTH103, a monoclonal antibody currently undergoing Phase 2 clinical trials for treating generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

Should You Invest $1,000 in Dianthus Therapeutics Now?

Before making any decisions regarding Dianthus Therapeutics, it is essential to consider this information.

Market trends show that top-rated analysts are currently highlighting several other stocks viewed as better investment opportunities than Dianthus Therapeutics.

View the recommended stocks for further insights.